Information
Address

Gustave Roussy
114, rue Édouard-Vaillant
94805 Villejuif Cedex - France
Switchboard:

Switchboard

+33 (0)1 42 11 42 11

GUSTAVE ROUSSY
1st cancer center in Europe

© 2006-2015 Gustave Roussy – All rights reserved

ASCO 2017
05/31/2017

ASCO 2017: the latest clinical advances in oncology

The leading experts on cancer treatment convene in Chicago in early June for ASCO Annual Meeting. Gustave Roussy will be alongside the principal contributors of this congress.

Résultats encourageants d’une immunothérapie contre les cancers gynécologiques

back to job offer list
back to clinical trials

Villejuif, may 30, 2017

ASCO 2017

Encouraging results for an immunotherapy in gynaecological cancer    

Nivolumab might be a new effective therapy in patients with failed  treatment of uterine cervical, vaginal and vulval cancers. On 2nd June  Dr Antoine Hollebecque, Head of the Day Hospital Unit in the Drug  Development Department (DITEP) at Gustave Roussy, will present these  results at an oral session at the ASCO Congress.

05/29/2017

De nouvelles armes contre la douleur

La lutte contre la douleur, aiguë ou chronique, est plus que jamais une priorité dans la prise en charge du cancer. Anesthésie locorégionale, nouveaux médicaments, neurostimulation, hypnose, sophrologie… Les approches se multiplient et se complètent pour l'attaquer sur tous les fronts.

Gustave Roussy à l'ASCO 2017 : dossier de presse

back to job offer list
back to clinical trials

Villejuif, le 29 mai 2017

Gustave Roussy à l'ASCO 2017

Comme chaque année depuis plus de 50 ans, les plus grands experts de la lutte contre le cancer ont rendez-vous à Chicago début juin au congrès annuel de l'American Society of Clinical Oncology (ASCO) pour échanger sur les dernières innovations cliniques en cancérologie.

Asco 2017 - A new predictive test for the risk of relapse in kidney cancer

back to job offer list
back to clinical trials

Villejuif, 1st june 2017

Gustave Roussy at ASCO 2017 - Videos

back to job offer list
back to clinical trials

Gustave Roussy presents at ASCO 2017 two studies showing the advantages of liquid biopsy (blood test) to detect genetic mutations in tumoral cells’ DNA in order to target the treatment and to monitor the disease. Prof. Benjamin Besse (Gustave Roussy, France) explanations.

ASCO 2017 - Press releases

back to job offer list
back to clinical trials

ASCO 2017 Press releases

 

Gustave Roussy at ASCO 2017

back to job offer list
back to clinical trials

As in every year for more than half a century, the leading experts on cancer treatment will convene in Chicago in early June to discuss the latest clinical advances in oncology.

ASCO 2017 - Metastatic melanoma: PD1-blocking immunotherapy confirms its long-term clinical efficacy, even after cessation of treatment

back to job offer list
back to clinical trials

Villejuif,  31 may 2017

Actualité : Les Cancers ORL
05/11/2017

Cancers ORL : retrouver une voix, un visage, une vie

Centre de référence national pour les cancers ORL rares, Gustave Roussy a acquis une expertise de premier plan sur ces pathologies variées, graves et complexes. Son département ORL prend en charge environ 1 200 nouveaux patients par an.

Pages